论文部分内容阅读
目的评价多西他赛+阿霉素+环磷酰胺(TCA)方案与环磷酰胺+5-氟尿嘧啶+甲氨喋呤(CMF)方案新辅助化疗(NC)治疗局部晚期乳腺癌(LABC)的临床疗效。方法对我院收治的术前行4个周期TCA或CMF方案新辅助化疗LABC患者89例的临床资料进行回顾性分析,随访资料完整的71例患者作为研究对象,其中TCA方案组33例,CMF方案组38例,比较2组患者客观缓解率(ORR)及术后总生存率(OS)。结果 TCA组和CMF组ORR分别为75.8%和52.6%,TCA组显著高于CMF组(P<0.05)。TCA和CMF组中位随访时间分别为35.4个月(4.1~58.2个月)和37.1个月(3.6~60.0个月);3年生存率分别为98.1%和83.6%,2组患术后死亡风险差别无统计学意义(HR=0.64,95%CI:0.22~1.84,P<0.05)。结论与CMF方案比较,TCA新辅助化疗可显著提高局部LABC患者的ORR,但远期生存率无明显差别。
Objective To evaluate the efficacy of docetaxel plus doxorubicin plus cyclophosphamide (TCA) regimen with cyclophosphamide plus 5-fluorouracil plus methotrexate (CMF) regimen with neoadjuvant chemotherapy (NC) in the treatment of locally advanced breast cancer Clinical efficacy. Methods The clinical data of 89 patients with neoadjuvant chemotherapy and LABC treated with TCA or CMF regimen in our hospital for 4 cycles were retrospectively analyzed. Among the 71 patients with complete follow-up data, 33 patients with TCA or CMF 38 patients in the program group were compared objective response rate (ORR) and postoperative survival (OS). Results The ORR of TCA group and CMF group were 75.8% and 52.6% respectively, which were significantly higher in TCA group than those in CMF group (P <0.05). The median follow-up time was 35.4 months (4.1-58.2 months) and 37.1 months (3.6-60.0 months) in the TCA and CMF groups, respectively. The 3-year survival rates were 98.1% and 83.6%, respectively Risk differences were not statistically significant (HR = 0.64, 95% CI: 0.22 to 1.84, P <0.05). Conclusion Compared with CMF regimen, neoadjuvant chemotherapy with TCA can significantly improve ORR in patients with local LABC, but there is no significant difference in long-term survival.